CK2 Inhibitor Design for Potency and Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CK2 inhibitors for cancer treatment have limitations in potency and specificity, with a need for novel compounds that can effectively target cancer cells and potentially overcome drug resistance, while also addressing inflammation, pain, and other diseases.
Innovation Solution
Development of novel 5-substituted aminopyrimido[6′,1′:2,3]imidazo[4,5-c][1,6]naphthyridine derivatives with specific structural formulas that inhibit CK2 enzyme activity, offering potent anticancer properties and potential applications in combination therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CK2 inhibitors are used for cancer treatment, then cancer therapy is provided, but potency and specificity are limited
Solution Approach 1:
The patent segments the CK2 inhibitor development by creating distinct series of compounds with different core structures (pyrimido-imidazo-naphthyridine, pyrido-imidazo-naphthyridine, pyrazino-imidazo-naphthyridine). Each series is optimized for specific potency and selectivity profiles, allowing tailored approaches to overcome different resistance mechanisms in cancer cells.
Solution Approach 2:
The patent systematically varies chemical parameters including substituent types (R1-R6 groups), positions of substitution, and core structure modifications to optimize the balance between potency, specificity, and ability to overcome drug resistance. This includes varying alkyl, aryl, heteroaryl groups and their positions to fine-tune inhibitor properties.
2Reliability
If novel CK2 inhibitor structures are developed, then potency against cancer cells is improved, but development complexity increases
Solution Approach 1:
The patent develops a universal core structure (imidazo[4,5-c][1,6]naphthyridine) that serves multiple functions: it provides potent CK2 inhibition, maintains cell permeability, and allows for diverse substituent attachment. This core structure can be used across multiple series (pyrimido, pyrido, pyrazino variants) to generate compounds with different specificities while maintaining the essential antitumor activity.
Solution Approach 2:
The patent applies local quality by introducing specific substituent groups at defined positions (R1-R6) on the core structure to enhance specific properties such as CK2 binding affinity, selectivity over other kinases, and metabolic stability, while keeping the core structure relatively simple and synthesizable.
3Reliability
If CK2 inhibitors are combined with other anti-cancer agents, then treatment effectiveness is enhanced, but therapy complexity increases
Solution Approach 1:
The patent merges the CK2 inhibition mechanism with other anti-cancer mechanisms by developing compounds that can be combined with standard therapies (alkylating agents, anti-metabolites, vinca alkaloids, taxanes, topoisomerase inhibitors, anti-tumor antibiotics, tyrosine kinase inhibitors, and immunosuppressive macrolides). This creates synergistic effects that enhance overall treatment effectiveness while managing complexity through systematic combination protocols.
Data Source
AI summary
Novel 5-substituted aminopyrimido[6′,1′:2,3]imidazo[4,5-c][1,6]naphthyridine compounds having the formula I below with all substituents as defined in the instant specification, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The 5-substituted aminopyrimido[6′,1′:2,3]imidazo[4,5-c][1,6]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.